| abstract |
The present invention relates to (i) a TGF-β antagonist that can inhibit TGF-β signaling, such as a TGF-β antagonist antibody, protein, peptide, or small molecule (ii) bound to a bone targeting moiety. Containing conjugates are provided. The bone targeting moiety localizes the TGF-β antagonist to bone tissue. The conjugates described herein provide a therapeutic paradigm for the treatment of various diseases associated with elevated TGF-β signaling and increased bone turnover, such as osteogenesis imperfecta and other bone lesions. [Selection] Figure 1 |